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Abstract
Background: Medullary thyroid cancer (MTC) is a C-cell neoplasm. Surgery remains its main treatment. Promising
therapies based on tyrosine kinase inhibitors demand careful patient selection. We previously observed that two
non-steroidal anti-inflammatory drugs (NSAID), indomethacin, celecoxib, and nitric oxide (NO) prevented tumor
growth in a model of human MTC cell line (TT) in nude mice.
Methods: In the present study, we tested the NO donor: glyceryl trinitrate (GTN), at pharmacological dose, alone
and in combination with each of the two NSAIDs on TT cells. We also assessed the anti-proliferative potential of
NO-indomethacin, an indomethacin molecule chemically conjugated with a NO moiety (NCX 530, Nicox SA) on
TT cells and indomethacin/GTN association in rMTC 6–23 cells. The anti-tumoral action of the combined sc.
injections of GTN with oral delivery of indomethacin was also studied on subcutaneous TT tumors in nude mice.
Apoptosis mechanisms were assessed by expression of caspase-3, TAp73α, TAp73α inhibition by siRNA or Annexin V
externalisation.
Results: The two NSAIDs and GTN reduced mitotic activity in TT cells versus control (cell number and PCNA protein
expression). The combined treatments amplified the anti-tumor effect of single agents in the two tested cell lines
and promoted cell death. Moreover, indomethacin/GTN association stopped the growth of established TT tumors in
nude mice. We observed a significant cleavage of full length PARP, a caspase-3 substrate. The cell death appearance
was correlated with a two-fold increase in TAp73α expression, with inhibition of apoptosis after TAp73α siRNA
addition, demonstrating its crucial role in apoptosis.
Conclusion: Association of NO with NSAID exhibited amplified anti-tumoral effects on in vitro and in vivo MTC
models by inducing p73-dependent apoptotic cell death.
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Introduction
Medullary thyroid carcinoma (MTC) is a neuroendo-
crine neoplasm of C cells (for reviews see [1, 2]). This
cancer releases large amounts of calcitonin (CT) corre-
lated to tumor size [3]. MTC is sporadic in about 75 %
of cases, and patients with sporadic carcinoma are usu-
ally diagnosed at late stage. Nowadays, surgical removal
of the thyroid with lymph node dissection is the gold
standard curative treatment of MTC. Prognostic remains
poor since 40 to 60 % of patients are not cured. Current
chemo- and radiotherapies are still ineffective. Heredi-
tary germ-line mutations or somatic mutations of the
RET proto-oncogene are involved in the carcinogenesis
of familial and sporadic MTCs respectively. Several tyro-
sine kinase inhibitors (TKIs) that are notably RET recep-
tor inhibitors are used and under evaluation for patients
with advanced MTC with promising results [2, 4]. Thus
TKIs vandetanib or cabozantinib can be used as single
agent for first line systemic therapy in selected patients
with advanced progressive MTC. But TKIs give only a
significant increase of progression-free survival with no
effect on death rate [5]. Thus, other or combined curative
approaches are necessary to improve MTC treatments in
the future.
The anti-tumor potential of non-steroidal anti-
inflammatory drugs (NSAIDs) was recognized a few
years ago [6–8]. The anti-proliferative effects of NSAIDs
can result from the decrease of prostaglandin (PG) syn-
thesis by inhibition of cyclooxygenase (COX) activity but
also from anti-tumoral actions independent of PGs and
COXs. We have previously demonstrated that the clas-
sical NSAID, indomethacin, reduced the development of
xenografted TT tumors induced by injection of human
MTC TT cells in nude mice [9]; indomethacin lowered
PGE2 secretion by TT cells. We also reported that a
low dose of the selective COX-2 inhibitor, celecoxib
(with less gastro-intestinal side effects than conventional
drugs) significantly diminished the growth of TT tumors.
This anti-tumor action was independent of PGE2 and
COX-2 [10].
Otherwise, we observed a very strong anti-tumor po-
tential of nitric oxide (NO) on MTCs for two rat cell lines
and TT cells [11]. More recently, authors reported that
the chemical association of NO donors with a NSAID
not only prevented side effects of the NSAID but also
was able to amplify its anti-tumor action [12–14]. Eleva-
tion of the NO concentration can cause DNA damage,
mutation and apoptosis [15]. The tumor suppressor pro-
tein p53 is a key player in the DNA damage response and
the onset of apoptosis. NO has been shown to activate
p53 which promotes pro-apoptotic effects [16]. Two p53
related genes, p63 and p73, have also been identified
more than 15 years after the discovery of p53 [17, 18].
The human p73 gene generates two groups of isoforms,
some with a complete transactivation (TA) domain
(TAp73) and others exhibiting a truncated TA domain
(ΔNp73). Growth suppression or induction of apoptosis
can be accomplished by the TAp73 isoforms. Studies
have shown that p73 is required for apoptosis induction
in response to DNA damage by chemotherapeutic drugs
such as cis-platin [19]. Thus, p53 and p73 could be inter-
esting targets to study in MTC chemotherapies: p53 is
not mutated in this cancer; in contrast, p73 was never
studied in C cell but mutations in the p73 gene are rare
in cancer patients. p73 is not only involved in tumor
suppression but has important functions in neural cells
and it also could be well expressed in neuroendocrine C
cells.
In the present study, we compared the anti-proliferative
actions of a pharmacological dose of the NO-donor,
glyceryl trinitrate (GTN) or Trinitrine, a drug used in
cardiology, of two NSAID, indomethacin and celecoxib,
of the combinations of one NSAID with GTN, and finally,
of a chemically conjugated molecule, NO-indomethacin
(NCX 530) from Nicox SA, an indomethacin molecule
conjugated with a NO donor group. We also studied the
implications of cell death mediators p53 and p73 in TT
cells. The NSAID doses used in these cultures were those
reproducing the anti-tumoral benefits with low side effects
we have previously described in vivo. Moreover, we
assessed the anti-proliferative effect of the indomethecin/
GTN association in another MTC cell line, rMTC 6–23
and studied the anti-tumoral action of a combined admin-
istration of GTN in sc. injections with oral delivery of
indomethacin on xenografted TT tumors.
Materials and methods
Materials
Celecoxib was a generous gift from Pfizer (USA). Indo-
methacin was purchased from Cayman Chemical (Ann
Arbor, MI). The NO-donor glyceryl trinitrate (GTN) was
obtained from Merck (Lyon, France). The conjugated
molecule NO-indomethacin (NCX 530) was a gift from
Nicox SA (Sophia Antipolis, France). The TT and rMTC
6–23 cell lines were from the American Type Culture
Collection (Rockville, MD). Primary antibodies to p73
(IMG 313A, Imgenex, A300-126A, Bethyl Laboratories),
p53 (sc 6243, Santa Cruz Biotechnology), PCNA (Santa
Cruz Biotechnology), PARP-1 (c-2-10, Calbiochem) and
α-tubulin (T9026, Sigma) were used for western blots.
Detections were performed with fluorescent Alexa Fluor
680-conjugated anti-mouse (A 21057, Invitrogen/Molecu-
lar Probes) or IRDye 800CW-anti-rabbit (926–32211, LI-
COR Biosciences) IgG. Rabbit anti-caspase-3 antibody
(ab52293, Abcam), Starr Trek Universal detection kit
(Biocare Medical/Eurobio) and AEC Peroxidase Substrate
kit (Vector Laboratories/Eurobio) were used for the im-
munohistochemitry of TT tumor slides.
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Cell culture
TT cells were cultured in RPMI 1640 medium (Invitrogen,
Cergy-Pontoise, France) supplemented with 2 mM L-glu-
tamine, 25 mM HEPES, 10 % heat-inactivated fetal calf
serum (FCS), 100 U/mL penicillin and 100 μg/mL strepto-
mycin (Invitrogen). RMTC 6–23 cells were cultured in
Dulbecco’s Modified Eagle’s medium (DMEM) Gluta-
MAX™ (Life Technologies, Cergy-Pontoise, France) sup-
plemented with 1 % of Non-Essential Amino Acids (Life
Technologies) and −5 % heat-inactivated FCS. To deter-
mine the anti-proliferative effects of the NSAID/GTN
combinations or NCX 530, TT or rMTC 6–23 cells were
seeded out in 6-well-plates at a density of 2 to 3 × 105 cells
per well, respectively. Three days later, NSAIDs and/or
GTN were added (or not, or vehicles only, for the con-
trols) to cell culture medium. Medium was changed every
two days (TT cells) or every 36 h (rMTC 6–23 cells). After
various periods of treatment, cells were dissociated 5 min
with trypsin-EDTA or TrypLE™ Express (Life Technolo-
gies) for TT or rMTC 6–23 cells, respectively. Cells were
counted with an hemocytometer (Trypan Blue exclusion)
and/or using counting slides with an automated cell
counter (TC20™ Bio-Rad, Marnes-la-Coquette, France).
NSAIDs were dissolved in DMSO and GTN in ethanol.
The following doses were used: celecoxib 25 μM, indo-
methacin 100 or 200 μM, GTN 100 μM, and NCX 530,
100 and 200 μM for short term experiments, and 150 μM
for long term experiments. Controls were performed in
the presence of drug vehicules (DMSO and ethanol)
at the same concentrations as in experimental wells
(DMSO ≤ 0.4 % and ethanol = 0.2 %). For western blot
analyses, cells were seeded out in 6-well plates at a dens-
ity of 106 cells per well. Treatments began 3 days later. In
proliferation and apoptosis detection experiments, tripli-
cates were performed for each category; in experiments
for immunoblotting analyses, duplicates were used.
Apoptosis detection
After cell counts, the cell suspensions were adjusted to
106 cells/ml in microfuge tubes. An Annexin V-FITC
Apoptosis Detection kit (Calbiochem, Merck Millipore,
Darmstadt, Germany), was used to quantify apoptosis/
necrosis. The “Rapid Annexin V binding” protocol pro-
vided by the suppliers was followed. After incubation
with Annexin V-FITC and addition of Propidium Iodide,
fluorescence was immediately analyzed by flow cytometry
(BD Accuri™ C6 Flow Cytometer, BD Biosciences) using
530/30 and 670 LP emission filters preventing spillover.
Unlabeled samples were used to adjust the gates.
Immunoblotting analyses
Immunoblots were performed as described in Tebbi et
al. [20]. After harvest, cells were washed twice in ice-
cold phosphate buffered saline (PBS). Crude cell extracts
were prepared in a 50 mM Tris–HCl lysis buffer,
pH 7.4, supplemented with 150 mM NaCl, 1 % Triton
X-100, 0.5 % sodium deoxycholate, 1 mM EDTA, 1 mM
DTT and protease inhibitors including 1 mM Pefablock
(Merck/Calbiochem). Soluble proteins (30 μg per lane)
were separated by SDS-PAGE using a 10 %-acrylamide
gel and transferred onto nitrocellulose membranes. These
ones were blocked in 3 % skimmed milk. After overnight
incubation at 4 °C with primary antibodies and four
washes in PBS/Tween, membranes were incubated for
1 h with fluorescent dye-conjugated secondary antibodies.
After washing, the infrared fluorescent signals at 680
and 800 nm were quantified with an Odyssey scanner
(LI-COR Biosciences). Protein contents were standard-
ized using α-tubulin band density.
Transfections with TAp73 siRNA
SiRNA sequences were reported and validated in Guittet
et al. [21]. Cells were transfected with TAp73 Select
siRNA (Ambion) or control siRNA (MWG) using Inter-
ferin transfection reagent (Polyplus Transfection). TT cells
were plated in 6-well plates and grown to approximately
30-50 % confluency. Before transfection, culture medium
was replaced by the same medium without antibiotics
(4 mL per well). Interferin (corresponding to 15 μL per
well) was incubated with siRNA for 10 min in antibiotic-
free medium. Then, the mixture was added dropwise to
wells, resulting in a siRNA concentration of 30 nM. We
have previously verified that this method led to 80 %
reduction of TAp73α expression, 3 days after mixture
addition. Cells were maintained in the transfection me-
dium for 16 h. They were then cultured in usual medium
with GTN (100 μM) and celecoxib (25 μM) treatment
or with DMSO and ethanol (control wells) during
2 days and 8 h.
In vivo experiment
5 × 106 TT cells were inoculated subcutaneously (sc) on
the back of each nude mouse. When tumors became
palpable, their diameters were regularly measured with a
caliper and tumor volume (mm3) was calculated using
the following formula: (the shortest diameter)2 × (the
longest diameter) × 0.5. When the mean volume of
tumors reached about 70 mm3, animals were randomly
divided into three groups: one control group (5) and two
treated groups, one receiving sc injections of Nitronal
each two days, (0.1 mg GTN/20 g of body weight during
6 days, then 0.15 mg, n = 5), the other group receiving
the same doses of Nitronal with indomethacin (2 mg/
day/kg of body weight in drinking water, n = 4). Animal
manipulations were performed according to the recom-
mendations of the French Ethical Committee and under
the supervision of authorized investigators.
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Mice were sacrificed at day 14 and tumors were re-
moved and weighted. Tumors were divided in two parts.
One part of the tumor was fixed in 4 % paraformalde-
hyde during 96 h and embedded in paraffin. Some tumor
slides, chosen in three different levels (100 μm apart),
were colored with hematotoxylin-phloxine-saffron (HPS)
stain. The cavity area of colored slides was measured
by ImageJ software at three levels in each tumor. For
caspase-3 immunohistochemistry, we followed a method
similar to that described in Bressenot et al. [22].
Statistical analyses
All results were analysed using ANOVA. Differences be-
tween two means were tested by the Fisher tests. Data
are represented as means ± SEM. For each determin-
ation, two or three independent experiments were per-
formed. The significance level was set at P < 0.05. For
the proliferation experiments, we assessed the differ-
ences between treated cells and control cells at day 4
(D4). We also tested cell number reductions induced by
NO-NSAID bi-therapies at D4 and D8 versus D0. For
the immunoblotting analyses, we tested the differences
between treated and control cells at D1 and D3. More-
over, for each NSAID/GTN combination (proliferation
experiments at D4 and p73 expression at D3), we per-
formed a two-factor variance analysis to assess the sig-
nificance of NSAID or GTN effects individually and to
test the presence of a NSAID/GTN interaction.
In the annexin V studies, a significant linear regression
was obtained between apoptotic cell percentages and
total number of cells, in controls: the apoptotic cell
percentage increases when cell density grows. Thus, we
compared the apoptotic cell percentage in each treated
culture with a percentage (calculated with the regres-
sion) in a control containing the same total number of
cells than the treated culture. For the in vivo experiment,
we assessed the tumor volume growth and the mean
differences between treatments by the two-factor ana-
lysis (time factor as repeated measures and treatment
factor).
Results
Anti-proliferative effects of GTN, NSAID/GTN
combinations and NO-indomethacin on TT cells
As previously reported, we observed that the NSAIDs
celecoxib and indomethacin prevented the proliferation
of TT cells: the cell number in treated samples was
reduced by about 30 % at D2 and D4 versus controls
(Fig. 1a and b). Moreover, we established that a NO-
donor, GTN (100 μM), had a similar effect: the viable
cell number was decreased by about 30 % versus con-
trols (Fig. 1a and b). We revealed significant effects of
each NSAID alone and GTN alone at D4. Interestingly,
the combinations of one NSAID with GTN strongly
increased the anti-tumoral action seen for each individ-
ual molecule at D4 (cell number diminution of 50 to
60 % versus controls). Significant reductions were ob-
served between D0 and D4, P < 0.05, after celecoxib/
GTN incubation and P < 0.01, after indomethacin-GTN
treatment. The two-factor analysis of variance did not
reveal an interaction between each NSAID and GTN; this
result suggests the presence of additive effects. NO-
indomethacin, NCX530, had the same anti-tumor action
than the GTN and indomethacin incubation. The reduc-
tion of cell population treated with NCX 530 versus
control was dose-dependent (Fig. 1c).
Continuous anti-tumor action of NSAID/GTN combina-
tions and NO-indomethacin after long-time administra-
tion on TT cells
When cells were treated with NO-NSAID combinations
until D8, the cell number reduction was prolonged from
D4 to D8: P < 0.05 for indomethacin/GTN, P < 0.01 for
celecoxib/GTN and NO-indomethacin alone (Fig. 2a). In
another experiment, TT cells were incubated with NSAID/
GTN combinations or NO-indomethacin during 7 days
then, cultured in drug-free medium until D12. Under these
conditions, no growth rebound was observed between D7
to D12 (Fig. 2b). Thus, the anti-tumoral action was am-
plified when treatments were prolonged and this beneficial
effect was maintained after treatment cessation.
NSAIDs, GTN and NSAID/GTN bi-therapies reduce mitotic
proliferation of TT cells. NSAID/GTN combined treatments
only lead to cell death
PCNA is a nuclear antigen expressed during cell mitotic
division. The effects of drug exposition on PCNA expres-
sion were investigated by western blot analysis. Figure 3a
shows a significant decrease in PCNA levels in all 3-day-
treated cells versus controls: celecoxib alone, P < 0.0001,
indomethacin alone, P < 0.0001, GTN alone, P < 0.0001,
NSAID/GTN combinations, P < 0.0001 (NCX 530, P <
0.01). Thus, all these treatments reduced the levels of TT
cell mitotic divisions.
PARP is a substrate of caspase-3, cleaved early during
cell apoptosis. Western blot analyses revealed that PARP
was cleaved in TT cells incubated with drug combinations
(or NO-indomethacin alone, data not shown) during
3 days: the levels of PARP full-length polypeptide were sig-
nificantly decreased (P < 0.05 versus control cells) for all
bi-therapies, (Fig. 3b). No effect appeared after one day of
treatment (data not shown). Thus, the reduction of viable
cell numbers receiving bi-therapies after D2 also resulted
from apoptotic cell death induction.
Increased expression of the tumor suppressors p53 and p73
We investigated the expression of the tumor suppressors
p53 and p73 in TT cells at basal levels and in response
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to the different treatments by NSAIDs and NO. We found
that this cell line expressed p53 and TAp73α at basal
levels. ΔNp73 was not detected in control and treated TT
cells. No change in p53 and p73 expressions was observed
in 1-day treated cells (data not shown). Indomethacin,
indomethacin plus GTN, and NO-indomethacin led to
comparable increases in p53 levels at D3 while celecoxib
and GTN had no effect (Fig. 3c).
In contrast, TAp73α expression increased by a factor two
after 3-day NSAID/GTN combined treatments (Fig. 3d)
or incubation with NO-indomethacin alone. These ele-
vations were correlated with a reduction in PARP levels
and TT cell number decrease between D2 and D4. The
two-factor analysis of variance showed significant 50 %-
increases of TAp73 level after 3-day treatments with
NSAID alone or GTN alone: in the experiments with
indomethacin plus GTN, P = 0.05 for indomethacin fac-
tor, P = 0.01 for GTN factor; in the experiment with
celecoxib plus GTN, P < 0.05 for celecoxib and for GTN.
No significant interaction between NSAIDs and GTN
was revealed. Thus, additive effects lead to the strongest
increases in TAp73 expression after 3-day combined
treatments.
p73 siRNA transfection
Celecoxib/GTN combination induced a strong and sig-
nificant increase of TAp73 expression in TT cells, after
2 days and 8 h of treatment (P < 0.01, Fig. 4a and b).
Transfection of siRNA targeting TAp73 isoforms before
this treatment, led to a significantly lower level of TAp73
(around minus 50 %, P = 0.05). We also observed a de-
crease of PARP heavy chain expression after the NSAID/
GTN incubation (P < 0.05, Fig. 4a and c), while TAp73
siRNA suppressed this phenomenon. Thus, as suggested
by the previously described correlation, the strong in-
crease in p73 level must be responsible for PARP cleavage
and cell apoptosis.
Confirmation of anti-proliferative effect of the indometh-
acin/GTN association on rMTC 6–23 cell cultures
Anti-proliferative actions of NO and indomethacin
were also assessed by incubations with indomethacin
alone (200 μM), GTN (100 μM) alone, or combina-
tions of the two drugs in a second MTC cell line (Fig. 5).
As observed in TT cells, indomethacine or GTN alone
slowed the growth of rMTC 6–23 cell cultures; the com-
bination amplified the anti-proliferative effect of each
Fig. 1 a Evolution of the number of viable, control or treated TT cells: 25 μM celecoxib, (cele), 100 μM GTN or a combination of celecoxib plus GTN,
during 4 days. b Evolution of viable TT cell number during 4-day treatments with 100 μM indomethacin (indo), 100 μM GTN or a bi-therapy of
indomethacin plus GTN. c Effects of the conjugated molecule (NO-donor conjugated to indomethacin, NCX 530), 100 μM (NO-indo100) or 200 μM
NO-indomethacin (NO-indo200), during the first 4 days of treatment. Representative graphs of three (a, b) or two (c) independent experiments
performed in triplicates. Adherent cells were dissociated with trypsin-EDTA and count with an hemocytometer with blue trypan exclusion.
* = P < 0.05, ** = P < 0.01, *** = P < 0.001 versus control (Fisher test)
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drug (P < 0.01 versus indomethacin alone, P < 0.0001 ver-
sus GTN alone, at D6) and even reduced the cell number
at D6 versus D0 (P < 0.05). The apoptosis percentage was
low, about 5 % in controls according to Annexin V stain-
ing and FACS analysis. Indomethacin did not produced
significant change in apoptosis level versus control while
GTN alone induced only a low elevation (145 %, P <
0.05) but the combination of both led to a stronger
increase (308 %, P < 0.001), at D6. This ampification was
significant (P < 0.01, combined treatment versus GTN
incubation). Thus, also in this cell line, the strong anti-
proliferative action of indomethacin/GTN association
resulted from the promotion of apoptotic cell death.
Anti-tumoral action of combined administration of GTN
plus indomethacin on established subcutaneous TT
tumors in nude mice
Next, the in vivo activity of GTN alone or in combin-
ation with indomethacin was determined in nude mice.
Figure 6 illustrated the effect of treatments on TT
xenograft volumes. Subcutaneous injections of GTN did
not significantly modified the growth of the subcutaneous
tumors while the bi-therapy first slowed it down and then,
stopped it from D7 to D12 (global analyses showed a sig-
nificant effect of the bi-therapy versus control, P < 0.0001
and a significant effect of the combination versus GTN
alone group, P < 0.05). Action on tumor weights at D14
Fig. 2 a Evolution of viable TT cell number in control wells and in wells treated by NSAID/GTN combination: 25 μM celecoxib plus 100 μM GTN
(cele + GTN), or 100 μM indomethacin plus 100 μM GTN (indo + GTN), or 150 μM NCX 530 (NO-indo), during 8 days. b Evolution of viable TT cell
populations after cessation of treatments with NSAID/GTN bi-therapies or NCX 530 (25 μM celecoxib, 100 μM indomethacin, 100 μM GTN or 150 μM
NCX 530). Representative graphs of two independent experiments performed in triplicates. Adherent cells were dissociated with trypsin-EDTA and
count with a hemocytometer. *** = P < 0.001 versus control for each treatment (Fisher tests)
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was strictly comparable to effect on tumor volumes at
D12 (data not shown).
A HPS coloration of slides showed that control TT tu-
mors were rather only composed of tumoral tissue. The
GTN-treated tumors had the same appearance. On the
contrary, numerous spaces empty of cancerous cells were
visualized in tumors treated by the drug combination. The
cavity area represented 19 ± 2.8 % of the total tumor sur-
face. In agreement with these observations, we found
numerous cleaved caspase-3 stained cells in these tumors
indicating that the combination led to cell death, probably
by apoptosis. Such immunostaining observations were
rare in the GTN-treated and control groups. The tumor
growth arrest with formation of cavities and presence of
Figure 3 Expression of various proteins in TT cells after 3 days of exposition to 25 μM celecoxib (cele), 100 μM indomethacin (indo),
100 μM GTN or NSAID/GTN combinations. a PCNA protein. For each category, n = 6 to 3. b PARP heavy chain. For each category, n = 4
to 3. c Tumor suppressor p53. For each category, n = 4 to 2. d TAp73α. For each category, n = 7 to 4. Graphs obtained from associated
results of two experiments on TT cells. Proteins from TT cell lysates were separated by SDS-PAGE using 10 % acrylamide gel and transferred
onto nitro cellulose membranes. Immunoblots were probed with specific antibodies and a α-tubulin (internal control) antibody. * = P < 0.05,
*** = P < 0.001 versus control (Fisher tests)
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Fig. 4 a Effect of p73 siRNA pre-treatment on TAp73 and PARP expressions in TT cells receiving 25 μM celecoxib plus 100 μM GTN (combi) during
2 days and 8 h. b Effect of p73 siRNA pre-treatment on TAp73 expression in the same TT cells. c Effect of p73 siRNA pre-treatment on full length
PARP expression in these cells. Graphs obtained from associated results of two experiments on TT cells. For each category, n = 6 to 4. Proteins
from TT cell lysates were separated by SDS-PAGE using 10 % acrylamide gel and transferred onto nitro cellulose membranes. Immunoblots were
probed with specific antibody and a α-tubulin (internal control) antibody. * = P < 0.05, ** = P < 0.01 (Fisher tests)
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apoptotic cells suggested that the combined treatment
reduced the cancer extension after D7 while GTN alone
had no significant effect.
Discussion
In the present study we demonstrated the anti-
proliferative value of NO donor plus NSAIDs on a
human MTC cell line. The bi-therapies, celecoxib/
GTN, indomethacin/GTN and NO-indomethacin
amplified the anti-proliferative effects of each drug alone
against TT cells. Indomethacin/GTN combination had
the same action on the growth of rMTC 6–23 cells. Since
the enhanced cytotoxicity of bi-therapies was correlated
with increased expression of TAp73 in TT cells, we pro-
posed that TAp73 might be implicated in the cytotoxic
mechanism. In support of this hypothesis, knocking
down TAp73 reduced PARP cleavage, a marker of apop-
totic cell death. Interestingly, the indomethacin/GTN
combination also produced a reduction of tumoral tis-
sue extension and induced cell death, in the in vivo
model. We have previously reported that the adminis-
tration of indomethacin alone at the same dose only re-
duced TT xenograft growth [9].
It has been widely shown that NSAIDs and aspirin
prevented the growth of numerous cancers and notably
human cancers. The anti-tumor and pro-apoptotic po-
tentials of NO have often been reported. During the last
few years, authors have tested various conjugated mole-
cules associating a NO-donor with a non-selective COX
inhibitor, i.e. classical NSAID (NO-NSAID). They de-
scribed that NO-NSAID have better anti-proliferative
activity than the parent NSAID, in vitro and in vivo,
and in particular, in colon, bladder and prostate cancer
[23–26, 13]. Moreover, the administration of NO reduces
the side effects of NSAID. Recently, the anti-proliferative
action of nitro-oxy derivatives of the COX-2 selective in-
hibitor, celecoxib, has been assessed in various cell lines.
These interesting derivatives of celecoxib which have less
toxicity than the parent NSAID, showed an anti-tumor
activity comparable to that of celecoxib [27, 28].
With respect to MTCs, our group has found that cele-
coxib at a low dose and the classical NSAID, indometh-
acin, reduced the development of tumors arising -from
human TT cell injection in nude mice [10, 9]. Tomoda
et al. [29] also reported that indomethacin have a strong
anti-proliferative action on TT cells and two other MTC
lines, due to mitotic division reduction without amplifi-
cation of cell death level. Moreover, we have observed
that three MTC cell lines were very sensitive to the anti-
proliferative effect of a NO-donor [11]. The present
publication reports that a pharmacological dose of GTN,
a NO pro-drug used in cardiology, reduced significantly
TT cell proliferation in vitro via mitotic division decrease.
Fig. 5 Evolution of the number of viable, control or treated rMTC 6–23
cells: 200 μM indomethacin (indo), 100 μM GTN, or the combination
of indomethacin plus GTN, during 6 days. Experiment performed in
triplicates. Adherent cells were dissociated with trypsin-EDTA and their
number was evaluated with a cell counter (blue trypan exclusion).
Drug combination amplified the anti-proliferative effect of each drug
(P < 0.01 versus indomethacin alone, P < 0.0001 versus GTN alone, at
D6) and reduced the cell number at D6 versus D0 (P < 0.05, Fisher tests)
Fig. 6 In vivo effect of GTN plus indomethacin association on growth of TT xenografts in nude mice. Indomethacin was administrated in drinking
water (2 mg/kg of body weight × day). Mice treated by GTN received Nitronal sc injections each two days (100 μl during the first week and
150 μl/20 g body weight the second week of treatment). a Effect on tumor volumes. The GTN-indomethacin/GTN association stopped the growth
of TT tumors from D7 to D12. Significant differences were revealed between tumor volumes by ANOVAs (P < 0.0001 combination group versus
control, P < 0.05 combination group versus GTN treated group; control group, n = 5, GTN treated group, n = 5 and indomethacin/GTN association,
n = 4). * = P < 0.05, ** = P < 0.01 (Fisher tests versus control at D9 or D12). b A microphotography of immunostaining of caspase 3 protein revealed
numerous apoptotic cells (dark dots) in indomethacin/GTN treated tumors. No staining was observed in the two other groups of tumor
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As previously described for other cancer cells, incubation
with NO and indomethacin strongly amplified the anti-
tumoral effect of treatments alone in TT cell cultures.
NO-indomethacin (NCX 530) had a stronger action than
the individual NSAID. Interestingly, in our model, the
association of GTN with celecoxib also increased the
anti-proliferative activity of the drugs used as single
agents. After analyses of the mitotic division and
apoptosis markers, PCNA and PARP, we found that
this phenomenon resulted from the induction of TT
apoptotic cell death by combinations of a NO donor
with each NSAID, while each molecule alone only
acted on mitotic division.
In cancer biology, both positive and negative actions of
NO have been reported. Low doses could promote cancer
proliferation. Elevation of NO concentration can cause
cell damage and apoptosis [15] and the tumor suppressor
protein p53 have been implicated in the onset of cell death
[16]. Recently, Tebbi et al. [20] described that NO induced
the overexpression of the tumor suppressor isoform
TAp73α in leukemia cells. In our model, the NO donor
GTN, at low dose, did not increase p53 expression and
only induced mitotic division reduction without apoptosis
induction. This treatment moderately elevated TAp73α
expression in TT cells but only after three days of expos-
ition. The pathway leading to in vitro proliferation re-
duction remains unknown. Anyway, only a moderate, not
significant growth reduction was obtained in vivo. This
result could come from the difficulties to reveal a signifi-
cant effect in vivo compared to in vitro experiment, from
lower NO doses in tissues but also from the promotion of
tumor angiogenesis which favors tumor cell proliferation.
The mechanisms of NSAID action are not completely
elucidated. The anti-tumor effect of these drugs can result
from the decrease of PG by inhibition of synthesis en-
zymes, COX 1 and/or 2. However, various mechanisms,
independent of PG and COX have been also described
[30, 31]. Increase of p53 expression was frequently ob-
served after NSAID treatments of various models. In
particular, Lau et al. [32] found that COX inhibitors
induce apoptosis by increasing p53 stability and nuclear
accumulation. Targeting p53 in MTCs may represent an
attractive strategy since this protein is not mutated in
these tumors [33]. In the present study, we found that
only indomethacin increased p53 expression, in TT cells.
Indomethacin alone acts on mitotic division [9]. However,
p53 level elevation did not seem to intervene in the cell
division reduction as this phenomenon appeared before
p53 level increase.
Recently for the first time, Lau et al. [34] demon-
strated the implication of p73 in the anti-tumor effect of
a NSAID: the apoptotic response to celecoxib resulted
from the increase of the TAp73β:ΔΝp73 ratio in neu-
roblastoma cells. In our hand, both celecoxib and
indomethacin increased the expression of the TAp73α iso-
form in TTcells. It is noteworthy that ΔΝp73 and TAp73β
were not detected in this cell line. The moderate elevation
of TAp73α expression by a 1.5 factor did not promote the
anti-mitotic action of the NSAIDs since this anti-tumor
effect appeared during the first day of treatment while the
variations in protein expression was only observed after
more than two days. However we have not investigated
post-translational modifications of TAp73α, such as phos-
phorylation that might be implicated in the anti-mitotic
effects of these NSAIDs. Moreover, in our model, the
increase of TAp73α after incubation with NSAIDs alone
did not induce cell apoptosis. In fact, TAp73α would be a
less potent apoptosis inducer than TAp73β [35].
Combinations of NO with one of the NSAIDs did not
reinforce the cell division reduction as PCNA level in
cells treated with only one simple drug was comparable
to the protein expression in cells which have received
combined treatment. But interestingly and for the first
time, we observed the addition of NO and NSAID effects
on TAp73α expression. Thus combinations led to a stron-
ger elevation of this isoform level. Bi-therapies only pro-
moted apoptosis resulting from the TAp73α expression
increase as demonstrated by full length PARP western
blot after TAp73α siRNA adjunction in TT cell cultures.
In the in vitro experiments, we used celecoxib and
indomethacin doses that reproduced anti-tumor effects
obtained for long term in vivo treatments; the NO-
donor GTN was used at a pharmacological dose. Thus,
the in vitro observations described here allow to study a
phenomenon that can be also induced in vivo as demon-
strated in our in vivo experiments. More in vivo valid-
ation has to be done but the bases are set to expect
similar results. The expression of p73 must also be veri-
fied in human MTCs.
It could be of interest for many reasons to consider
clinical studies with NSAID and/or NO-donor therapies.
First, these drugs have a low cost and are currently used
with many years of experience in healthy subjects. Sec-
ond, these drugs could be used for a long period at all
stage of the disease (advanced or not). Third, combined
anti-proliferative actions of NO donor and NSAIDs dem-
onstrated in this study seem independent of known ac-
tions of TKI and synergic actions with them could be of
value [36]. Unfortunately, clinical experience with use of
indomethacin in patients with recurrent or metastatic
MTC has been limited to three cases. In only two out of
three patients, indomethacin therapy for 3 or 4 months
caused marked reduction in tumor mass as well as calci-
tonin levels [37]. The efficacy of these drugs remains to
be determined by clinical trials.
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